News | December 30, 2022
Cipla EU to invest € 15 million in Ethris
Cipla and Ethris partner for the development of mRNA-based therapies
Cipla and Ethris partner for the development of mRNA-based therapies
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The organisation is also working towards providing skills based training programmes to the workers for paramedical jobs and has launched certificate courses in ten disciplines
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients
Post the sale, Patel family has become the single largest promoter shareholder in the company
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
Subscribe To Our Newsletter & Stay Updated
